New study findings may pave the way for research into the prognostic value of white matter lesions in heart failure and the impact that HF therapies have on them.
Having a history of heart failure (HF) is independently associated with white matter lesions (WML), according to new findings published in ESC Heart Failure. The findings, say the researchers, may pave the way for research into the prognostic value of WML in HF and the impact that HF therapies have on WML, as WML can have negative implications for cognitive and physical functioning.
The finding comes from the German population–based LIFE-Adult Study of 10,000 patients, 2500 of which underwent cerebral MRI and had WML measured by Fazekas score, which ranges from 0 to 3 based on the overall burden of a patient’s WML.
HF (odds ratio [OR], 2.8; 95% CIU, 1.2-6.5; P = .019) joined the ranks of older age (OR, 1.099; 95% CI, 1.078-1.120; P ≤ 0.001), hypertension (OR, 2.0; 95% CI, 1.5-2.8; P < . 001), and stroke (OR, 2.0; 95% CI, 1.0-4.1; P = .05) as being independently associated with WML. More than one-third (40%) of patients with HF had a WML Fazekas score of 2-3, indicating severe WML, compared with 15.1% of those without HF.
HF remained independently associated with WML even when including atrial fibrillation (AF) in the model. AF originally was flagged as being independently associated with WML in univariate analysis but was no longer independently associated after adjusting for age and gender. This remained true when including HF in the model.
“Contrary to our initial expectations, our results showed no association between AF and WML after adjustment for age, gender, stroke, and hypertension,” wrote the researchers. “WML may develop in AF by silent brain infarcts, mostly in patients not on anticoagulation.”
The findings also indicated that the duration of HF, not just the prevalence, has implications for WML. A HF duration of less than 3 years was associated with an OR of 0.8 (95% CI, 0.1-7.5), while having HF for 4 to 6 years was associated with an OR of 1.6 (95% CI, 0.3-9.6) and having HF for more than 6 years, an OR of 2.9 (95% CI, 1.1-7.9; P = .036).
Meanwhile, the risk of WML with hypertension was not impacted by the duration of the condition, with an OR of 2.0 (95% CI, 1.3-3.2; P = .002) for hypertension duration of less than 3 years, 2.2 (95% CI, 1.4-3.4; P < .001) for duration of 4 to 6 years, and 1.9 (95% CI, 1.4-2.6; P < .001)for duration of more than 6 years.
“Consistent with our findings, previous studies reported associations of increased systolic blood pressure and age with WML,” commented the researchers. “For instance, a previous study reported an increased risk for WML with longer duration of hypertension while we did not observe that the patients in the LIFE-Adult Study may had well-diagnosed and well-controlled hypertension, while poor control of blood pressure was associated with WML.”
Other factors, like gender, body mass index, myocardial infarction, and diabetes, were not associated with WML.
Reference
Stegmann T, Chu ML, Witte VA, et al. Heart failure is independently associated with white matter lesions: insights from the population-based LIFE-Adult Study. ESC Heart Fail. Published online December 15, 2020. doi:10.1002/ehf2.13166
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Patients With HFpEF May Benefit From Accelerated Cardiac Pacing
August 28th 2025In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics
August 13th 2025Clinical trial results establish the safety and efficacy of finerenone to help preserve potassium levels and reduce sodium in patients on diuretics with heart failure and mildly reduced ejection fraction or preserved ejection fraction.
Read More
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More